Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Key Research Features Triple-hormone receptor agonist GIP + GLP-1 + Glucagon (GCGR) Tuned potency hierarchy across all three receptor targets C20 fatty diacid moiety albumin binding, ~6-day half-life in research models Simultaneous energy intake and energy expenditure pathway modeling 99% HPLC-verified purity LC-MS sequence and molecular weight identity confirmed Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, Retatrutide should be: Stored at 20C in a tightly sealed container Protected from light and moisture Reconstituted in sterile or bacteriostatic water Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information Currently an Investigational New Drug (IND) under active Phase 3 clinical investigation (TRIUMPH and TRANSCEND trial series) Not FDA-approved for any therapeutic indication as of current date Prohibited by the World Anti-Doping Agency (WADA) under S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics Supplied strictly as a Research Use Only (RUO) material Why Choose Summit Pep Labs
One of the main roadblock with peptide drugs are clearance and abilities to penetrate the bbb
Regulating Appetite Signals Retatrutide targets the brains appetite centers and hormone pathways
Many treatment plans combine classes under clinical supervision
Prior authorization through your Part D plan is typically required to access the bridge benefit
Choi YB, Lipton SA (2000)
